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IGF II mRNA-binding protein 3 (IMP-3) has been reported to be a marker of melanoma progression. However, the
mechanisms by which it impacts melanoma are incompletely understood. In this study, we investigate the clinical
significance of IMP-3 in melanoma progression and also its underlying mechanisms. We found that IMP-3
expression was much higher in advanced-stage/metastatic melanomas and that it was associated with a poor
prognosis (P¼ 0.001). Univariate analysis showed that IMP-3 expression was associated with stage III/IV
melanomas (odds ratio¼ 5.40, P¼ 0.031) and the acral lentiginous subtype (odds ratio¼ 3.93, P¼ 0.0034). MeWo
cells with overexpression of IMP-3 showed enhanced proliferation and migration and significantly increased
tumorigenesis and metastatic ability in nude mice. We further demonstrated that IMP-3 could bind and enhance
the stability of the mRNA of high mobility group AT-hook 2 (HMGA2). It was also confirmed that IMP-3 had an
important role in melanoma invasion and metastasis through regulating HMGA2 mRNA expression. IMP-3
expression was positively correlated with HMGA2 expression in melanoma cells and also in melanoma tissues.
Our results show that IMP-3 expression is a strong prognostic factor for melanoma, especially acral lentiginous
melanoma.
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INTRODUCTION
Cutaneous melanoma is the most aggressive skin neoplasm
refractory to traditional therapies, especially at the metastatic
stage. Furthermore, the incidence of cutaneous melanoma has
continuously increased during the last decade (Miller and
Mihm, 2006; Gray-Schopfer et al., 2007). Because of the
intractability of metastatic melanoma, only 14% of patients
survive for 5 years (Miller and Mihm, 2006). Understanding
the underlying molecular mechanisms involved in melanoma
progression and the identification of molecular markers are
important for improvements in therapies for metastatic
melanomas.
IGF-2 mRNA-binding protein 3 (IMP-3) is a 580 amino-acid
protein encoded by a 4,350-bp mRNA transcript produced by
a gene located on chromosome 7p11.5-a locus frequently
amplified in melanoma (Mueller-Pillasch et al., 1997; Nessling
et al., 2005; Jeng et al., 2008). IMP-3 is expressed in a wide
range of mouse and human fetal tissues in a time-dependent
and cell-dependent manner, but it is undetectable in human
adult tissues (Mueller-Pillasch et al., 1997, 1999). IMP-3
appears to have an important role in the differentiation and
maturation process during early embryogenesis as a trans-
lational activator of IGF-2 leader-3 mRNA (Pryor et al., 2008).
Increased levels of IMP-3 have been identified in many
cancers, including human leukemia, pancreatic cancer, gastric
cancer, and colorectal cancer (Jonson et al., 2014). In a recent
study, depletion of IMP-3 using RNA interference in the
hepatocellular carcinoma cell line, HA22T, caused a decrease
in cell motility, decreased invasion, and decreased trans-
endothelial migration (Jeng et al., 2008). IMP-3 depletion
was associated with downregulation of CXCL5, interleukin 8,
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epidermal growth factor, and high mobility group AT-hook 2
(HMGA2; Jeng et al., 2008).
Recently, IMP-3 has been claimed to be a diagnostic clue in
cutaneous melanocytic neoplasms because of its expression in
malignant melanomas, but not in benign melanocytic nevi,
even when dysplastic features are present (Pryor et al., 2008;
Yu et al., 2010). Furthermore, IMP-3 is expressed in meta-
static melanomas significantly more than in thin melanomas
(Pryor et al., 2008). However, the mechanism by which
IMP-3 is involved in melanoma progression is not fully
understood. Recently, IMP-3 ribonucleoproteins were found
to function as cytoplasmic safe houses that prevent
microRNA-directed HMGA2 mRNA decay during tumor
progression (Jonson et al., 2014). In this study, we confirm
that IMP-3 expression is a poor prognostic factor in
melanomas, especially acral lentiginous melanoma (ALM). In
addition, IMP-3 expression promotes migration and invasion
of melanoma cells by a pathway of modulating the expression
of HMGA2 mRNA.
RESULTS
IMP-3 correlates with melanoma progression and predicts poor
prognosis
The expression of IMP-3 in a spectrum of 147 cutaneous mela-
nocytic lesions, including nevus, melanoma in situ, primary
melanoma, and metastatic melanoma, was examined (Supple-
mentary Table S1 online). With the exception of two Spitz
nevi that were positive for IMP-3, all other benign, dysplastic,
and Spitz nevi were negative for IMP-3, as visualized after
immunostaining (Figure 1a and b). Melanoma in situ had
weak cytoplasmic expression of IMP-3 (Figure 1c). The
percentage of melanoma cases that showed IMP-3 positivity
in at least 10% of tumor cells was related to melanoma
progression from 50% (11/22) in superficial melanoma
(depthr1.0 mm; Figure 1d), 83% (61/75) in deep melanomas
(depth41.0 mm; Figure 1e), to 96% (25/26) in metastatic
melanomas (Figure 1f).
Samples from a total of 97 patients with primary cutaneous
melanoma were collected and analyzed (Table 1). ALM was
the most common subtype (74/97, 76.3%), followed by
nodular melanoma (12/97, 12.4%), superficial spreading
melanoma (8/97, 8.2%), and lentigo maligna melanoma
(3/97, 3.1%). The mean age of the patients in each subtype
was 64.2, 56.9, 53.0, and 63.3, respectively. Extremities were
the most commonly involved locations in these melanoma
patients (85/97, 87.6%). The mean Breslow thickness of all
tumors was 3.94 mm.
To examine the clinical significance of melanoma IMP-3
expression, the correlation between several important clinico-
pathological variables and IMP-3 expression was analyzed
using logistic regression (Table 1). IMP-3 expression was signi-
ficantly associated with the ALM subtype (odds ratio¼3.93,
95% confidence interval¼1.11–13.94; P¼0.0034) and with
advanced-stage melanoma (odds ratio¼ 5.40, 95% confi-
dence interval¼1.17–24.87; P¼ 0.031). However, IMP-3
expression was not correlated with age, sex, ulceration, lymph
node metastasis, or tumor thickness. The median duration of
patient follow-up after diagnosis of melanoma was 5.2 years
(range, 0.4–18.1 years). The 5-year overall survival rate in 97
patients with melanoma was 51.5%. When stratified by
positive (n¼ 72) and negative (n¼ 25) IMP-3 expression, the
5-year overall survival rate of patients with melanoma was
41.7% and 80.0%, respectively. Following Kaplan–Meier
analysis, patients who were positive for IMP-3 expression
had significantly reduced overall survival compared with
those patients who were negative for IMP-3 expression
(Figure 1g; P¼ 0.001). Univariate analysis using a Cox regres-
sion model showed that lymph node metastasis, advanced
melanoma stage, and IMP-3 expression were predictive of
poor outcomes. Because IMP-3 expression was demonstrated
to be associated with advanced melanoma stage, only age and
clinical staging were the strongest individual clinical factors
that were found in the multivariate analysis (Supplementary
Table S2 online).
IMP-3 expression correlates with the migration, invasion,
tumorigenicity, and metastatic abilities of melanoma cells
To confirm the functional importance of IMP-3 in melanoma
cells, IMP-3 expression was examined in different melanoma
cell lines. Melanoma cells characterized by higher migratory
and invasive ability (RPMI7951, A375, and A2058) had
increased IMP-3 expression compared with those melanoma
cells with lower migratory/invasive abilities (C32 and MeWo;
Figure 2a). Transient transfection of small interfering RNA
against IMP-3 into A2058 cells successfully knocked down the
expression of IMP-3 and also inhibited the migratory/invasive
abilities of A2058 cells (Figure 2b). Stable clones of IMP-3
overexpressing MeWo cells (MeWo/IMP-3) with increased
IMP-3 protein levels also showed enhanced cell proliferation
and migratory abilities compared with the vector clone
(MeWo/vec; Figure 2c and d). Furthermore, examination of
tumorigenicity in vivo using subcutaneous injection of MeWo
cells into the footpads of nude mice revealed that MeWo/IMP-
3 xenografts were significantly larger compared with those
formed by MeWo/vec cells 2–6 weeks post inoculation
(Figure 2e). In a lymph node metastasis model, footpad
injection of MeWo/IMP-3 cells resulted in significantly more
popliteal lymph node metastasis compared with the MeWo/
vec cells (Figure 2f and g).
Identification of endogenous RNA targets for IMP-3
To better understand the mechanism by which IMP-3 med-
iates melanoma progression, cDNA microarray analyses were
performed to compare the mRNA profiles of MeWo/IMP-3 and
MeWo/vec cells. A hierarchical clustering analysis was used
by selecting probes with a greater than 2-fold change in
MeWo/IMP-3 cells compared with MeWo/vec cells, which
revealed 49 annotated genes (Supplementary Figure S1 online
and Supplementary Table S3 online). Of the 26 significantly
upregulated genes and 23 downregulated genes in MeWo/
IMP-3 cells, 6 were previously known to contribute to
migration, invasion, and metastasis (Figure 3a). Considering
that all three IMPs have similar RNA-binding domain
sequences and are capable of binding to human IGF-2 mRNA
with high affinity in vitro, it has been suggested that IMP-3 and
IMP-1 may share the same RNA targets, such as c-myc and
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IGF-2 mRNAs (Liao et al., 2005). To verify the microarray
findings, the expression of the selected six genes and c-myc
was analyzed using quantitative real-time reverse-trans-
criptase–PCR (qRT–PCR), which demonstrated that IMP-3
overexpression in MeWo cells was associated with elevated
HMGA2, c-myc, and TGF-b2 mRNA levels compared with
MeWo/vec control cells (Figure 3b). Elevated HMGA2, c-myc,
and transforming growth factor-b2 (TGF-b2) protein levels in
MeWo/IMP-3 cells were also confirmed by western blot
analysis (Figure 3c).
To identify the in vivo RNA targets of IMP-3 and to confirm
an association between IMP-3 protein with HMGA2, TGF-b2,
and c-myc mRNAs in melanoma cells, RNA-binding protein
immunoprecipitation/qRT–PCR analyses were employed using
anti-human IMP-3 antibody or control IgG and cytoplasmic
lysates of A2058 cells. As shown in Figure 4a, anti-human
IMP-3 antibody precipitated HMGA2, TGF-b2, and c-myc
mRNAs, whereas the control IgG did not precipitate these
RNAs. Real-time qRT–PCR-based quantitation of the immu-
noprecipitate revealed a 32.4-fold enrichment of the HMGA2
mRNA in A2058 cells upon immunoprecipitation with anti-
IMP-3 antibody, thereby establishing a direct association
between the IMP-3 protein and the HMGA2 mRNA
(Figure 4a). To confirm that IMP-3 targeted mRNA regulation
is also associated with HMGA2 expression levels in wild-type
melanoma cell lines, A2058 cells with high IMP-3 expression
were compared with MeWo cells, which have low IMP-3
expression. Higher HMGA2 expression was observed
in A2058 cells (Figure 4b). Transfection of IMP-3 siRNA
(siIMP-3) in A2058 cells also decreased HMGA2 protein and
mRNA expression (Supplementary Figure S2 online). There-
fore, we investigated whether IMP-3 regulates HMGA2 mRNA
stability. To address this point, we examined the stability of
the HMGA2 mRNA in A2058 cells. The mRNA stability levels
were quantified after treatment with siIMP-3 or control-
scrambled small interfering RNA. In the A2058 cells treated
with siIMP-3, HMGA2 mRNA decayed as a function of time.
In contrast, A2058 cells treated with scrambled small inter-
fering RNA stabilized the HMGA2 mRNA about 3-fold to
increase its expression (Supplementary Figure S3 online).
These data indicated that IMP-3 enhances the stability of the
mRNA of HMGA2 in melanoma.
IMP-3 binds to IGF-2 mRNA in vitro (Nielsen et al., 1999,
2004), and it associates with the leader-3 and leader-4
isoforms of IGF-2 mRNA in vivo (Liao et al., 2005).
Activation of IGF-2 mRNA translation driven by IMP-3 was
previously found to result in the modulation of cellular
functions such as proliferation and tumorigenic activity (Liao
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Figure 1. IGF II mRNA-binding protein 3 (IMP-3) is expressed in malignant melanoma and is correlated with its progression and prognosis. Benign melanocytic
nevi such as intradermal nevus (a) or dysplastic nevus (b) are negative for IMP-3. (c) Melanoma in situ has only weak cytoplasmic expression of IMP-3. (d) Focal
IMP-3 expression found in superficial malignant melanoma (Breslow depth %1 mm). (e) Strong and diffuse cytoplasmic expression noted in deep malignant
melanoma (Breslow depth41 mm). (f) Metastatic melanoma expresses IMP-3 in 490% of tumor cells (bar¼10mm). (g) Poor prognosis in cutaneous melanoma is
predicted by IMP-3 expression. Kaplan–Meier survival analysis of 97 primary cutaneous melanomas revealed that patients with positive IMP-3 expression have
significantly worse overall survival compared with those negative for IMP-3 (P¼ 0.001, log-rank test).
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et al., 2005; Suvasini et al., 2011). In contrast to a previous
report, overexpression of IMP-3 in MeWo cells did not
change intracellular or secreted IGF-2 levels (Figure 4c).
IMP-3 overexpression had no significant effect on IGF-2
leader-3 or leader-4 mRNA levels compared with the mock
treatment (Figure 4d). These results suggest that the phenotypic
effects of IMP-3 are not mediated by IGF-2 signaling in
MeWo cells.
IMP-3 enhances migration and invasion of melanoma cells
through HMGA2 regulation
To verify the involvement of HMGA2 in IMP-3-mediated
migration of melanoma cells, we co-transfected shHMGA2
or shLuc with IMP-3-expressing or vector control plasmids into
MeWo cells, and we found that knockdown of HMGA2
expression by shHMGA2 abolished the IMP-3-mediated mel-
anoma migration (Figure 5a and b). In addition, co-transfec-
tion of HMGA2-expressing plasmid with siIMP-3 in A2058
cells restored the inhibitory effects of siIMP-3 on A2058
migration/invasion (Figure 5c and d). In contrast, transfection
of shHMGA2 alone inhibited the migratory/invasive abilities
of A2058 cells (Supplementary Figure S4 online). These data
confirm that IMP-3-mediated melanoma migration/invasion
involves HMGA2.
Correlation of IMP-3 and HMGA2 expression of human
melanomas
Immunohistochemical examination of human melanoma tis-
sues demonstrated that tumor cells with high IMP-3 levels
(Figure 5e) also had high HMGA2 expression (Figure 5f),
whereas those with low IMP-3 levels (Figure 5g) had weak or
negative HMGA2 expression (Figure 5h). Using the collected
97 human melanoma samples, a positive correlation of IMP-3
and HMGA2 expressions in melanoma was found (P¼ 0.003,
Supplementary Table S4 online). qRT–PCR of melanoma
tissues from 25 patients also showed a strong positive correla-
tion between IMP-3 and HMGA2 mRNA levels (Supple-
mentary Figure S5 online).
DISCUSSION
Recently, IMP-3 has been found to be expressed in metastatic
melanomas significantly more than in thin melanomas (Pryor
et al., 2008). Another study has also showed that 50% of deep
melanomas (Breslow depth41 mm) and metastatic melanomas
demonstrate strong IMP-3 staining, whereas none of the
benign nevi were positive for IMP-3 (Yu et al., 2010). A
global genomic study characterizing primary and metastatic
melanomas revealed that IMP-3 was one of the validated
genes with pro-invasion activities (Kabbarah et al., 2010).
These results suggest that IMP-3 is a progression marker in
malignant melanoma (Pryor et al., 2008). Given that the
etiology and biological course of melanoma vary greatly
between different ethnic groups, the application of these
results to melanoma patients of across ethnic backgrounds
needs to be reassessed, especially in those with high pre-
valence of ALM. We currently report that IMP-3 is a poor
prognostic indicator of malignant melanoma, especially for
ALM.
Few studies have investigated the functional mechanisms of
IMP-3 as they relate to cancer progression (Jeng et al., 2008;
Jonson et al., 2014), and the role of IMP-3 in controlling
melanoma progression has not been addressed. We currently
demonstrate that IMP-3 promotes migration and invasion of
melanoma cells in vitro. Overexpression of IMP-3 in a mela-
noma cell line with low metastatic potential also enhanced
tumorigenicity and lymph node metastasis in vivo. Our data
also indicate an association between IMP-3 expression and
cell migration, invasion, and the metastatic potential of
melanoma cells, and therefore it related to poor prognosis.
The oncogenic effects of IMP-3 have been suggested to be
mediated through IGF-2 levels, the mRNA for which is
translationally activated by IMP-3 (Liao et al., 2005).
However, it has also been reported that IGF-2 protein levels
do not change significantly in IMP-3-depleted or over-
expressed hepatocellular carcinoma cells (Nessling et al.,
2005; Jeng et al., 2008). Our results are consistent with this
Table 1. Univariate analysis of IMP-3 expression and
risk factors of melanoma (N¼ 97)
IMP-3 expression
Characteristic Total Yes, n (%) OR (95% CI) P-value
Age (years)
X65 51 42 (82.4) 2.48 (0.97–6.38) 0.058
o65 46 30 (65.2) 1.0
Sex
Male 58 46 (79.3) 1.97 (0.76–4.81) 0.166
Female 39 26 (63.4) 1.0
Ulceration
Yes 31 24 (77.4) 1.29 (0.47–3.50) 0.623
No 66 48 (72.7) 1.0
Tumor thickness (mm)
44 31 26 (78.8) 1.29 (0.47–3.50) 0.623
p4 66 46 (71.9) 1.0
Lymph node metastasis
Yes 21 19 (90.5) 4.12 (0.87–19.17) 0.071
No 76 53 (69.7) 1.0
Tumor stage
III, IV 25 25 (92.0) 5.40 (1.17–24.87) 0.031*
I, II 72 49 (68.1) 1.0
Subtype
LMM 3 3 (100) — 0.999
NM 12 6 (50.0) 1.0 —
SSM 8 4 (50.0) 1.0 (0.17–5.99) 1.000
ALM 74 59 (79.7) 3.93 (1.11–13.94) 0.0034*
Abbreviations: ALM, acral lentiginous melanoma; CI, confidence interval;
IMP-3, IGF II mRNA-binding protein 3; LMM, lentigo maligna melanoma;
NM, nodular melanoma; OR, odds ratio; SSM, superficial spreading
melanoma.
*Po0.05.
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finding in that IMP-3 overexpression also had no significant
effect on IGF-2 protein and mRNA levels in MeWo
cells. Therefore, the malignant properties conferred by IMP-3
are not attributable to the effect of IGF-2 in MeWo melanoma
cells.
To identify the potential targets of IMP-3, we examined the
mRNA expression profile of IMP-3-overexpressed cells and
identified transcripts upregulated by IMP-3 overexpression,
which were previously identified to be involved in tumor
progression (Tureci et al., 2002; Wang et al., 2012; Assi et al.,
2013; Frewer et al., 2013; Ma et al., 2013; Raskin et al.,
2013).
Of these, HMGA2 is the most consistently upregulated
transcript and protein, which is an architectural transcription
factor and has a critical role in growth during embryonic
development (Zhou et al., 1995). HMGA2 is normally
expressed at low levels in adult tissues, but disruption of the
gene by chromosomal rearrangements at 12q13-15 and
overexpression of the protein result in benign mesenchymal
tumors such as lipoma, uterine leiomyoma, and pulmonary
chondroid hamartoma (Fedele et al., 2001). Further supporting
a role of HMGA2 in oncogenesis, the inhibition of HMGA2
blocked retrovirus-induced neoplastic transformation (Berlingieri
et al., 1995). Together with the proposed critical role of HMGA2
in embryonic growth, these observations suggest that HMGA2
overexpression is tumorigenic in differentiated tissues where
HMGA2 expression is normally undetectable. It is worth noting
that Jeng et al. observed that all HMGA2-positive hepatocellular
carcinomas were also IMP-3 positive, which suggests that IMP-3
may be a crucial factor in the regulation of HMGA2 expression
(Jeng et al., 2008).
An important consideration on the basis of the findings
described here is whether IMP-3 interacts directly with HMGA2
or regulates its expression indirectly. Our data demonstrate
that IMP-3 binds to HMGA2 mRNA and, as a consequence,
regulates its expression. We also found that IMP-3 expression
stabilized mRNA of HMGA2 in A2058 cells. Similar to IMP-3,
HMGA2 is also an oncofetal protein that is typically
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Figure 2. IGF II mRNA-binding protein 3 (IMP-3) enhanced aggressiveness of melanoma cells. (a) Melanoma cells with higher migratory/invasive abilities
demonstrated higher expression of IMP-3. (b) Transient transfection of small interfering RNA (siRNA) against IMP-3 inhibited the migratory/invasive abilities of
A2058 cells. (c) MeWo/IMP-3 cells showed enhanced migratory abilities. (d) Overexpression of IMP-3 in MeWo cells had significant change on cell proliferation.
*Po0.05, n¼3. (e) MeWo/IMP-3 xenografts were larger compared with MeWo/vec at weeks 2–6. (f) MeWo/IMP-3 cells resulted in larger popliteal lymph node
(LN) metastasis compared with the MeWo/vec cells (n¼ 10). (g) Upper panel shows representative HMB-45 immunostaining for lymph nodes taken from the two
groups. The MeWo/IMP-3 group had positive HMB-45 staining in all collected 10 lymph nodes, whereas only 2 of the 10 mice in MeWo/vec group had positive
staining. T, tumor; Vec, vector.
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downregulated in normal adult tissues and reactivated in
various cancers (Raskin et al., 2013). IMP-3 locasomes may
function as cytoplasmic safe houses that prevent microRNA-
directed HMGA2 mRNA decay during tumor progression
(Jonson et al., 2014).
Functional experiments further demonstrated the impor-
tance of HMGA2 activation for IMP-3-mediated melanoma
migration and invasion. We conclude from these data that
IMP-3 promotes progression in melanoma by regulating
HMGA2. It has been demonstrated that HMGA2 is highly
overexpressed in melanoma and is strongly associated with
regional and distant metastases (Raskin et al., 2013). HMGA2
overexpression has also been demonstrated to be positively
associated with BRAF/NRAS mutations (Raskin et al., 2013).
However, ALM accounted for around 76% of all melanoma
patients in the current study. It is noteworthy that the
frequency of BRAF mutations detected in the ALM was only
15–22% in previous studies (Si et al., 2012). We also found
that only 14.4% of melanoma patients had BRAF V600E/
V600K and that only 12.4% had NRAS Q61R/Q61L/Q61H/
G13D mutations in this study. HMGA2 overexpression was
not associated with BRAF or NRAS mutations in our study
population (Supplementary Table S5 online).
Treatment of melanoma patients remains a challenge
because of the paucity of targeted therapeutic options and
the high metastatic potential of melanoma. Although IMP-3
expression is correlated with the aggressive behavior of many
cancers and is used clinically for the prognostic assessment of
specific cancers, the mechanism by which it functions in this
context has remained elusive. We currently demonstrate that
IMP-3 promotes the progression of melanoma by regulat-
ing HMGA2. Targeting IMP-3 might offer a potentially
feasible and effective approach to the clinical management
of melanoma.
MATERIALS AND METHODS
Patients and tissues
This study was approved by the Research Ethics Committee of the
National Taiwan University Hospital and was conducted according to
the Declaration of Helsinki Principles. All melanoma patients
enrolled in the study provided written informed consent to use their
resected tissues. A total of 97 patients with primary cutaneous
melanoma at the National Taiwan University Hospital diagnosed
between January 1995 and November 2009 were enrolled. All
participating patients received standard-of-care treatment and surgical
excision of the primary lesion. Tissue sections for immunostaining
were obtained from formalin-fixed and paraffin-embedded primary
human tumors. Overall survival data were collected from chart
reviews and the Taiwan Cancer Registry.
Establishment of IMP-3 overexpression MeWo cells
The IMP-3 expression plasmid (pCMV-IMP3) was kindly provided by
Dr Yung-Ming Jeng (Jeng et al., 2008). pCMV-IMP3 was transfected
into MeWo cells using the Lipofetamine 2000 reagent (Invitrogen,
Carlsbad, CA). Stable clones of the above cell lines were selected
using puromycin.
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signaling pathway protein-2. Data are presented as relative changes to the control and are shown as mean±SD of three independent experiments. *Student’s t-test,
Po0.05.
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Microarray experiment
RNA from MeWo/IMP-3 was labeled by Cy5 and RNA from MeWo/
vec was labeled by Cy3. One microgram of total RNA was amplified
by a Quick-Amp Labeling kit (Agilent Technologies, Santa Clara, CA)
and labeled with Cy3 or Cy5 (CyDye, Perkin Elmer) during the in vitro
transcription process. A total of 0.825 mg of Cy-labeled cRNA was
fragmented to an average size of about 50–100 nucleotides by
incubation with fragmentation buffer at 60 1C for 30 minutes. Corre-
spondingly, fragmented labeled cRNA is then pooled and hybridized
to Agilent Human Whole Genome Oligo 4 44 K microarray (Agilent
Technologies) at 65 1C for 17 hours. After washing and drying by
nitrogen gun blowing, microarrays are scanned with an Agilent
microarray scanner (Agilent Technologies) at 535 nm for Cy3 and
625 nm for Cy5. Scanned images are analyzed by Feature extraction
10.5.1.1 software (Agilent Technologies). An image analysis and
normalization software were used to quantify signal and background
intensity for each feature, substantially normalizing the data by means
of the rank-consistency-filtering LOWESS method. A comprehensive
description of the methodology and analysis tools corresponding to
the data were deposited in National Center For Biotechnology
Information’s Gene Expression Omnibus under the accession number
GSE62574.
Statistical analysis
All statistical analyses were carried out using SPSS version 20.0
software (IBM, Armonk, NY). A two-tailed Student’s t-test was used
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for simple comparisons between two values where appropriate. All
data were expressed as mean±SD from at least three independent
experiments. Associations between pairs of categorical variables were
assessed with Pearson’s w2 test or Fisher’s Exact Test. Survival
probabilities were estimated using the Kaplan–Meier method and
were analyzed by log-rank tests. The influence of each variable on
survival was assessed using a multivariate Cox proportional hazard
model. All statistical tests were two-sided, and a P-value of 0.05 or
less was considered to be statistically significant.
Detailed description of sample preparation, mouse models, RNA-
binding protein immunoprecipitation, as well as western blot analy-
sis, mutational analysis, qRT–PCR, and immunohistochemistry, can
be found in Supplementary Methods online.
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